Bionetix, ProQinase, and MercachemSyncom announce a joint research project from target Identification to clinical study
Bionetix announced they have signed a joint multiyear integrated drug-discovery project, starting from target identification (TI) up to clinical candidate selection on an undisclosed target aimed at acute myeloid leukemia (AML).
MercachemSyncom closes acquisition of Alcami Weert
It is our great pleasure to announce today that MercachemSyncom has acquired Alcami’s European cGMP CMC drug substance development site, based in Weert, the Netherlands.
